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ABSTRACT 
 
Context: WNT signaling is fundamental to bone health and its aberrant activation leads to skeletal 
pathologies. A heterozygous missense mutation p.C218G in WNT1, a key WNT pathway ligand, 
leads to severe early-onset and progressive osteoporosis with multiple peripheral and spinal 
fractures. Despite the severe skeletal manifestations, conventional bone turnover markers are 
normal in mutation-positive patients.  
 
Objective: This study sought to explore the circulating miRNA pattern in patients with impaired 
WNT signaling.  
 
Design and Setting: A cross-sectional cohort study at a University Hospital. 
 
Participants: Altogether 12 mutation-positive (median age 39 years, range 11–76 years) and 12 
mutation-negative (35 years, range 9–59 years) subjects from two Finnish families with WNT1 
osteoporosis due to the heterozygous p.C218G WNT1 mutation.  
 
Methods and main outcome measure: Serum samples were screened for 192 miRNAs using 
qPCR. Findings were compared between WNT1 mutation-positive and mutation-negative subjects. 
 
Results: The pattern of circulating miRNAs was significantly different in the mutation-positive 
subjects as compared with the mutation-negative subjects with 2 upregulated (miR-18a-3p, miR-
223-3p) and 6 downregulated miRNAs (miR-22-3p, miR-31-5p, miR-34a-5p, miR-143-5p miR-
423-5p, miR-423-3p). Three of these (miR-22-3p, miR-34a-5p, and miR-31-5p) are known 
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inhibitors of WNT signaling: miR-22-3p and miR-34a-5p target WNT1 mRNA and miR-31-5p is 
predicted to bind to WNT1 3’UTR.  
 
Conclusions: The circulating miRNA pattern reflects WNT1 mutation status. The findings suggest 
that the WNT1 mutation disrupts a feed-back regulation between these miRNAs and WNT1, 
providing new insights into the pathogenesis of WNT-related bone disorders. These miRNAs could 
offer future potential in diagnosis and treatment of osteoporosis.  
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Précis 
This study reports a unique serum expression pattern of 8 circulating miRNAs in WNT1 mutation-
positive subjects and a novel finding of a communication between WNT1 and miR-31-5p.  
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INTRODUCTION 
 
Bone health is maintained by precisely balanced bone formation and resorption. In addition to key 
regulatory pathways and endocrine factors, microRNAs (miRNAs) have recently emerged as 
integral modulators of bone metabolism (1,2). MiRNAs are short, noncoding RNA fragments that 
regulate target gene expression by posttranscriptional silencing or repression of protein translation 
and serve important functions in various biological processes (3). In bone, miRNAs regulate both 
osteogenesis during fetal development and maintenance of bone health postnatally (3-6). In vitro 
studies further demonstrate their direct role in regulation of osteoblast and osteoclast development, 
maturation, and function (7-11). Furthermore, some clinical studies suggest that expression levels of 
different miRNAs associate with idiopathic and postmenopausal osteoporosis, correlate with bone 
mineral density (BMD), and differentiate between patient cohorts (12-16). Based on these 
observations miRNAs have been anticipated to have applications in the diagnosis and treatment of 
bone diseases, including osteoporosis (12,16).  
 
Canonical WNT/-catenin pathway is a key regulator of bone metabolism and defective WNT 
signaling underlies several monogenic skeletal disorders with low or high bone mass, such as 
osteoporosis-pseudoglioma syndrome, van Buchem disease, and sclerosteosis (18-20). In 2013, our 
research group identified WNT1 as a major regulator of bone mass as a heterozygous missense 
mutation p.C218G in WNT1 was shown to lead to decreased activity of the WNT/-catenin pathway 
in bone, resulting in low bone turnover with decreased number of bone cells and impaired bone 
formation, and consequently low bone mass and skeletal fragility (21). The mutation was first 
reported in a large Finnish family exhibiting severe, early-onset osteoporosis, multiple peripheral 
and spinal compression fractures, and subsequent loss in adult height (21,22). Despite the low BMD 
and significant skeletal pathology, the conventional bone biomarkers currently in clinical use, such 
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as alkaline phosphatase (P-ALP), the bone formation marker N-terminal propeptide of type I 
procollagen (PINP), and the bone resorption marker type I collagen cross-linked N-telopeptide 
(INTP), do not differ between WNT1 mutation-positive and mutation-negative individuals (21,22).  
 
Recent in vitro studies show that specific miRNAs regulate WNT signaling by binding to the 
pathway’s key components and inhibitors: miR-152-3p and miR-335 to Dickkopf-1, miR-30e-5p to 
low-density lipoprotein-receptor 6, and miR-27a-3p, miR-142, and miR-135a to adenomatous 
polyposis coli (23-28). Data on miRNA expression and circulating miRNA levels in genetic bone 
diseases are, however, still scarce (29). In patients with altered WNT signaling, miRNA profile, 
miRNAs’ potential role in disease pathogenesis, clinical diagnostics and follow-up remain unknown 
and previously unexplored. To gain more insight to the clinical relevance of miRNAs in inherited 
bone diseases with defective WNT signaling, we assessed miRNA profiles in subjects with a 
heterozygous WNT1 mutation and their mutation-negative family members.  
 
SUBJECTS AND METHODS 
 
Subjects. We have previously identified two large Finnish families with autosomal dominant 
WNT1 osteoporosis (21,22). The first family (Family A) was identified in 2013 as a novel 
heterozygous missense mutation p.C218G in WNT1 was identified by linkage analysis and targeted 
sequencing as the cause for severe early-onset osteoporosis in a family with 10 affected family 
members (21). We have since offered genetic screening to all first-degree relatives at risk and, 
subsequently, 21 additional mutation-positive family members have thus far been identified (Family 
A). A second family (Family B) was found to harbor the same exact point mutation as the whole 
WNT1 gene was Sanger sequenced for > 250 other Finnish index patients with osteoporosis. In this 
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family, 4 subjects have so far been found to harbor the same mutation. Hence, to date, altogether 25 
mutation-positive subjects with the heterozygous p.C218G have been identified in Finland.  
 
For the study, we offered all mutation-positive subjects from Family A and Family B the 
opportunity to participate in a study concerning miRNA studies in search for new bone biomarkers 
associated with the heterozygous WNT1 mutation. A control group with similar age and sex 
distribution was formed by offering the mutation-negative subjects in Family A (n = 29) and Family 
B (n = 3) also the opportunity to participate. Altogether 17 mutation-positive and 18 mutation-
negative individuals consented.  
 
All participants filled out a questionnaire with the following information: other diagnosed diseases, 
all previous fractures, all previous surgeries, previous bisphosphonate or other osteoporosis 
medication, other medication, and calcium and vitamin D supplementation. Based on these 
anamnestic data, we aimed to exclude subjects with fractures or orthopedic surgeries in the past 12 
months, or possibly confounding illnesses or medications.  
 
Genetic evaluations. We screened all participating study subjects for the heterozygous missense 
mutation c.652T>G (p.C218G) in exon 4 of WNT1 (NCBI Reference Sequence NM_005430.3). We 
performed genetic validations on DNA extracted from peripheral blood as previously described 
(22).  
 
Serum samples. We collected all serum samples during the spring season (January-April) in 2017 
to avoid bias from variable sunlight exposure. All samples were taken after a 12-hour fast, in the 
morning between 0800 h and 0900 h. Venous blood was first collected into normal serum tubes and 
left to stand in room temperature for 30-60 minutes to allow clotting. The tubes were then 
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centrifuged at 2500 x g for 10 minutes in room temperature and the supernatant was transferred to 
1.5 ml tubes in 250 µl aliquots. The serum was immediately stored at -80°C until analysis.  
 
Blood biochemistry. We assessed blood biochemical values from separate peripheral blood 
samples for serum calcium, phosphate, alkaline phosphatase (ALP), 25-hydroxyvitamin D (S-D-25; 
assessed with immunochemiluminometry), and 1,25-dihydroxyvitamin D (S-D-1,25; assessed with 
immunochemiluminometry); results were compared with laboratory’s reference values. Serum 
parathyroid hormone (PTH) and collagen type 1 cross-linked C-telopeptide (CTX-1; a bone 
resorption marker) were analyzed with an IDS-iSYS fully automated immunoassay system 
(Immunodiagnostic Systems, Ltd., Bolton, UK) with chemiluminescence detection and compared 
with manufacturer’s reference values. Serum intact Fibroblast growth factor 23 (FGF23) was 
assessed by manual enzyme-linked immunosorbent assay (ELISA; Immutopics International, San 
Clemente, California, USA; and Kainos Laboratories, Tokyo, Japan); the manufacturer’s reference 
values were used.  
 
miRNA analysis. We isolated RNA from the serum samples using the miRNeasy Mini Kit 
(Qiagen, Germany). Serum samples were thawed on ice and centrifuged at 12,000g for 5 minutes to 
remove any cellular debris. For each sample, 200 µL of serum was mixed with 1000 µL Qiazol and 
1µL synthetic Spike-Ins (Exiqon, Denmark). After a 10-minute incubation at room temperature, 
200 µL chloroform were added to the lysates followed by cooled centrifugation at 12,000g for 15 
minutes at 4°C. Precisely 650 µL of the upper aqueous phase were mixed with 7 µL glycogen 
(50mg/mL) to enhance precipitation. Samples were transferred to a miRNeasy mini column, and 
RNA was precipitated with 750 µL ethanol followed by washing with RPE and RWT buffer. RNA 
was eluted in 30 µL nuclease free water and stored at -80°C until further analysis. 
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Starting from total RNA samples, we synthesized cDNA using the Universal cDNA Synthesis Kit II 
(Exiqon, Denmark). We chose reaction conditions according to recommendations by the 
manufacturer. The protocol was modified in that 4µL of total RNA was used per 10 µl reverse 
transcription (RT) reaction. To monitor RT efficiency and presence of impurities with inhibitory 
activity, a synthetic RNA spike-in (cel-miR-39-3p) was added to the RT reaction. PCR 
amplification was performed in a 384-well plate format using custom Pick&Mix plates (Exiqon, 
Denmark) in a Roche LC480 II instrument (Roche, Germany) and EXiLENT SYBR Green 
mastermix (Exiqon, Denmark) with the following settings: 95°C for 10 min, 45 cycles of 95°C for 
10 s and 60°C for 60 s, followed by melting curve analysis. To calculate the cycle of quantification 
values (Cq-values), the second derivative method was used. Cq-values were normalized to the mean 
Cq-value in each sample (global mean normalization) by subtracting the individual miRNA Cq-
value from the Cq average calculated for that sample. Experimental design, platform description, 
and raw as well as normalized data have been submitted to Gene Expression Omnibus according to 
MIQE guidelines (accession number GSE103473). 
 
Statistical analysis. We used ClustVis to perform exploratory data analysis (30). PCA and 
hierarchical clustering analyses were performed using the default settings, i.e. singular value 
decomposition with imputation, correlation as the distance metric, and average distance for 
clustering. Group-wise differential expression analysis was performed based on global mean 
normalized delta Cq-values under the assumption of normal distribution, which was assessed 
visually, using two-sided t-tests. Receiver operator characteristic (ROC) analysis was performed in 
order to evaluate the power of selected circulating miRNAs to distinguish WNT1 mutation-positive 
subjects from mutation-negative subjects. ROC analysis was performed using MedCalc Statistical 
Software version 18 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018) to 
compute area-under-the-curve (AUC) values. 
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Study approval. All genetic and clinical studies were approved by the Research Ethics Board of 
Helsinki University Hospital. All subjects gave a written informed consent prior to participation in 
the study.   
 
RESULTS 
 
Clinical and biochemical characteristics 
We recruited study subjects from two families with autosomal dominant WNT1 osteoporosis. Based 
on pedigree analysis, we selected 12 mutation-positive (hereafter referred to as MP) and 12 
mutation-negative (hereafter MN) family members for the analyses (Figure 1, Table 1), aiming at 
comparable age- and sex distribution in the MP and MN groups. The selected subjects were 
negative for all four (22 subjects) or for three (2 subjects) of the following exclusion criteria: 1) a 
fracture in the past 12 months, 2) bisphosphonate or other osteoporosis medication in the past 12 
months, 3) hypothyroidism, and 4) use of aspirin or other possibly confounding medication. The 
MP cohort thus represented approximately half of all Finnish subjects identified with a WNT1 
mutation. 
 
The MP group comprised 7 females and 5 males (age range 11–76 years, median 39 years) and the 
MN group 5 females and 7 males (age range 9–59 years, median 34,5 years) (Table 1, Figure 1). 
The MP subjects had DXA-measured BMD values ranging from normal to osteoporosis (Z-score <-
2.5), a history of multiple fractures and other skeletal manifestations, but none had had fractures or 
orthopedic surgeries in the past 12 months and none had other confounding illnesses (Supplemental 
Table 1). Regarding medications, 3 MP subjects had received previous osteoporosis medication 
more than 12 months prior to the study, while 1 subject (MP-4) had received the most recent dose 
of low-dose pamidronate treatment (1 mg/kg once every 4 months) 3 months prior to the study. 
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Another male subject (MP-13) used aspirin. Serum 25-OH-vitamin D concentration in the MP 
group was slightly higher (90 nmol/L vs. 68 nmol/L) than in the MN group as the MP subjects also 
received, on average, a higher vitamin D supplementation (53 ug/day vs. 9 ug/day). Other 
parameters of calcium homeostasis and bone turnover, including S-D-1,25, PTH, and CTX-1, and 
intact FGF23 were similar in MP and MN groups (Table 1, Supplemental Figure 1). In the MN 
group, 7/12 subjects had previously been assessed with DXA or spinal MRI with no signs of 
osteoporosis or spinal compression fractures (Supplemental Table 1) (21,31). 
 
Quality control of miRNA quantitation 
We used a previously described analytical workflow to screen 192 distinct microRNA species and 
controls in the 12 MP and 12 MN subjects (14). Spike-in controls added prior to RNA extraction, 
reverse transcription and qPCR amplification were used to assess the technical variance of the 
workflow (Supplemental Figure 2) and identify potential outliers. We observed low technical 
variance in spike-in controls (11–23% coefficient of variation (CV)). To exclude a potential bias in 
our data due to hemolysis, we used the method reported by Blondal et al. of calculating a hemolysis 
index based on the ratio of miR-451a versus miR-23a-3p (32,33). None of the samples exhibited a 
ratio of >7, which would indicate hemolysis. The overall sensitivity of the analysis was very good. 
Only in 6 out of 24 samples missing values for low abundant miRNAs were observed. The 
maximum number of missing miRNA values observed in any sample was 2 out of 192 analyzed 
miRNAs (Supplemental Data 1).  
 
Exploratory data analysis 
We performed unsupervised exploratory data analyses in the form of principal component analysis 
(PCA) and hierarchical clustering to assess the overall impact of the MP subjects’ WNT1 mutation 
on circulating miRNA patterns in comparison to the MN subjects. Using data from the 50 most 
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variable miRNAs (sorted by CV%), we observed that the overall circulating miRNA levels were not 
significantly determined by WNT1 mutation status, sex, or subfamily division (Figure 2A, 
Supplemental Figure 3). However, group-wise comparison of circulating miRNA levels between 
MP and MN subjects identified a balanced number of up- and down-regulated miRNAs (Figure 
2B). In total, this screening, after applying a low-stringent p-value cut-off of <0.1 to reduce the 
number of false-negatives (Table 2), identified 16 putative miRNAs which together enabled good 
discrimination between MP and MN subjects (Figure 3A). 
 
Two of these miRNAs (miR-18a-3p, miR-223-3p) were significantly upregulated (p<0.043), while 
5 miRNAs (miR-22-3p, miR-34a-5p, miR-423-5p, miR-423-3p, miR-143-5p) were significantly 
down-regulated (p<0.045) in MP subjects (Figure 3B–I). Two miRNAs, miR-22-3p and miR-34a-
5p, were found to exhibit good classification performance with AUC-values reaching 0.896 and 
0.868, respectively. Correlation between the significantly regulated miRNAs was observed at 
varying, moderate degree, suggesting that some single miRNAs might contain information derived 
from different phenotypic characteristics caused by the WNT1 mutation (Supplemental Table 2). 
Ongoing low-dose bisphosphonate treatment in one mutation-positive female (MP-4) had no effect 
on miRNA values (Supplemental Figure 4) 
 
In silico prediction of miRNA targets 
We used Targetscan release 7.1 to identify predicted miRNA binding sites in the 3’UTR of human 
WNT1 gene (34). The tool reported putative binding sites for three miRNAs – miR-22-3p, miR-
34a-5p, and miR-31-5p – which we found to be down-regulated in serum of the MP subjects. For 
miR-34a-5p and miR-22-3p, binding to and regulation of WNT1 has been experimentally validated 
(35-38). For miR-31-5p, experimental confirmation of a direct interaction with WNT1 has not been 
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previously reported, while its interference with the WNT signaling ligand Frizzled 3 (FRZ3) has 
been observed (9). 
 
DISCUSSION 
 
This study is the first to report on miRNA profiles in subjects with a monogenic bone disease due to 
defective WNT signaling. All our mutation-positive subjects harbored a heterozygous missense 
mutation p.C218G in WNT1, which has been previously shown to lead to decreased WNT signaling, 
low bone formation, low BMD and fractures (21,22) while the mutation-negative subjects have 
normal BMD and no fractures (21,31). We screened a custom-designed panel of 192 miRNAs and 
compared the results between 12 mutation-positive and 12 mutation-negative subjects. Our results 
show that a unique profile of eight miRNAs differentiates between mutation-positive and mutation-
negative subjects and that three of these miRNAs – miR-22-3p, miR-34a-5p, and miR-31-5p – are 
down-regulated in serum in mutation-positive subjects (p=0.001, p=0.003, and p=0.053, 
respectively). All three miRNAs are known inhibitors of WNT signaling and miR-22-3p and miR-
34a-5p have been shown to target WNT1 specifically (35-38). To the best of our knowledge, no 
previously published data have reported direct association between miR-31-5p and WNT1. 
 
Recent research has found circulating miRNAs as promising new markers in various diseases, 
including malignancies, as many conventional biomarkers have shown limitations in diagnostics 
and in evaluating treatment outcomes (29). Regarding bone health and disease, current conventional 
metabolic bone markers are inadequate in reflecting bone health status, predicting future fracture 
risk, or monitoring treatment efficacy (12,39,40). Circulating miRNAs show promise as future bone 
markers, as specific miRNAs that discriminate e.g. patients with manifest osteoporosis (14,16,41), 
have also been shown to influence bone metabolism in vitro (1,13,14,24,42-43) and in vivo (41,16).  
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This suggests that circulating miRNA-based biomarkers might have causal links to the disease 
phenotype, as miRNAs packaged in extracellular vesicles or in protein particles can be taken up by 
recipient cells in auto-, para-, or even endocrine manner (45).   
 
Of the 8 miRNAs identified in our study as discriminating between MP and MN subjects, 7 have 
been reported to influence bone metabolism (Table 3). Interestingly, 3 of the downregulated 
miRNAs in the MP subjects have been confirmed or predicted to directly target WNT signaling 
and, specifically, WNT1 mRNA. For one, miR-22-3p negatively regulates osteogenesis and 
osteoblastogenesis through WNT signaling by targeting the coding region and suppressing the 
expression of -catenin, which inhibits formation of calcium nodules during osteoblast 
differentiation (10). miR-22-3p also targets and decreases the levels of Tcf7 and Ep300, which are 
key transcriptional proteins for WNT pathway’s target gene expression (46). Further, the 3’UTR of 
WNT1 contains a binding site for miR-22-3p and miR-22-3p directly targets WNT1 (35). Secondly, 
miR-34a-5p interacts with WNT pathways components (47) and also, directly with WNT1 to 
regulate its mRNA expression and posttranscriptional translation (36-38). Lastly, Weilner et al. 
showed that miR-31-5p interacts with a WNT pathway component Frizzled-3 (FZD3) and 
suppresses WNT signaling (9), while Xi et al. showed miR-31-5p to target WNT pathway 
antagonists Dkk-1 and DACT3 in lung cancer cells (48). However, unlike miR-22-3p and miR-34a-
5p, no previous findings of miR-31-5p directly targeting WNT1 have been reported.  Intriguingly, 
our findings suggest that decreased WNT signaling due to mutated WNT1 leads to downregulation 
of the miRNAs that exhibit suppressive action on the WNT pathway. This could be regarded as an 
attempt to normalize WNT signaling in a situation where WNT1-related WNT signaling is 
impaired. The molecular and genetic feedback mechanisms, including gene regulation by miRNAs, 
governing balanced bone metabolism are inadequately understood.  
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To the best of our knowledge, miR-423-3p, which was significantly downregulated in our mutation-
positive subjects, has not been previously linked to bone metabolism or WNT signaling. Wang et al. 
previously reported that miR-423-3p expression changed with age in mouse bone marrow 
mesenchymal stem cells’ microvesicles but no evidence for its effect on osteogenesis was shown 
(49). Also, other studies have reported that miR-423-3p is linked to myocardial tissue and heart 
diseases (50,51), but no specific heart phenotype or increased prevalence of myocardial diseases 
was observed in our cohort or in other WNT1 mutation-positive subjects (21,22). Therefore, this is 
the first study to suggest an association between miR-423-3p and WNT pathway.  
 
Prior or on-going osteoporosis medication could potentially alter an individual’s miRNA 
expression, although the mechanisms and exact consequences are still unclear (52). Our cohort 
included altogether 3 subjects with previous osteoporosis medication and 1 subject with on-going 
low-dose pamidronate treatment at the time of the study. Separate analysis showed that 
bisphosphonate treatment had no impact on the expression of the 8 specific miRNAs in our cohort 
and therefore the observed differences between MP and MN groups are unlikely to be related to the 
patients’ medical therapy. We have previously shown that conventional bisphosphonates have little 
to no effect on the BMD status in WNT1 mutation-positive patients (22). 
 
The therapeutic potential in miRNAs has been contemplated and experimentally tested in previous 
studies; Krzeszinski et al. could attenuate postmenopausal osteoporosis in ovariectomized mice 
with administration of systemic miR-34 (53), Wang et al. showed anabolic potential of anti-miR-
214 in stimulating bone formation in mice (54), and Wang et al. demonstrated protection against 
glucocorticoid-induced bone loss with miR-29a in rats (42). In a wider context, miRNAs are used 
clinically in cancer treatment as replacement therapies, to sensitize tumors to chemotherapy, and to 
treat drug-resistant malignancies (42). Whether these miRNAs up- or down-regulated in our study 
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could have therapeutic potential – as drug targets or exogenously administered medications – in 
WNT1 or other forms of osteoporosis should be explored in future experimental settings.  
 
Our study provides novel data on miRNA expression levels in WNT-related bone disease. The 
study could have been strengthened by larger cohort sizes and with only subjects with no 
confounding factors, such as osteoporosis medication. We did however exclude subjects with recent 
fractures and showed that subjects with previous or ongoing osteoporosis medication did not differ 
in their miRNA pattern from the others. Further, in order to minimize the impact of other 
confounding genetic factors, we recruited the MN subjects from the same families as MP subjects. 
We also consider the pre- and post-menopausal status in female subjects as a possible confounding 
factor. However, the two cohorts were very similar in age and gender distribution, alleviating the 
possible bias. Furthermore, there is no overlap with the miRNAs reported in this study and those 
previously reported to have alternate expression due to changes in estradiol concentration in Finnish 
subjects (55). The small sample size may have prevented us from observing some important 
differences between the groups, leading to a high false-negative rate. We tried to account for this by 
allowing relatively high type-I error (p<0.1) for initial selection. An independent cohort of WNT1 
MP/MN subjects would be required to validate miR-22, miR-34a and miR-31 findings. However, 
due to the scarcity of subjects with confirmed WNT1 or other WNT pathway-related osteoporosis, 
such a study was not possible. Despite these limitations and acknowledging the worldwide rarity of 
WNT1 osteoporosis, WNT1 mutation-positive individuals, and the overall scarcity of miRNA data 
in monogenic bone disorders, we consider our study setting and findings valid and valuable. 
 
We conclude that a unique miRNA profile is observed in WNT1 mutation-positive individuals 
compared to healthy individuals. These observations provide valuable information about the 
molecular pathways involved in WNT1 osteoporosis and the effect of aberrant WNT signaling on 
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miRNA expression. Our data also provides a novel finding of an association between WNT1 and 
miR-31-5p and miR-423-3p expression. The specific miRNAs highlighted in this study could serve 
as circulating metabolic bone markers in WNT1 osteoporosis to evaluate bone health, fracture 
healing, and treatment efficacy in affected individuals. Future studies are encouraged to further 
explore these specific miRNAs in other WNT pathway –related skeletal diseases, their response to 
anti-osteoporosis treatment, and their potential utilization in the development of osteoporosis 
treatment. 
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FIGURE LEGENDS 
 
Figure 1. Pedigrees of the families with a heterozygous p.C218G WNT1 mutation. Squares 
represent males, circles females, black symbols mutation-positive family members, white symbols 
mutation-negative family members, grey symbols mutation-negative healthy controls, and slashes 
deceased family members. Subjects included in this study are indicated with codes, MP = mutation-
positive, MN = mutation-negative. The pedigree has been altered to ensure anonymity. 
Family A
Family B
= mutation-positive
= mutation-negative
= mutation-negative, healthy control 
in study
MN-13
MP-17
MP-4 MP-2 MP-1
MP-6MN-12
MP-5 MP-3
MP-7
MP-15
MP-9
MP-13
MP-12
MN-2MN-3 MN-6 MN-7MN-8
MN-15
MN-11
MN-14MN-16MN-17
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Figure 2. A) Hierarchical clustering and heatmap representation of 187 circulating microRNAs, 
with labelling of genotype, sex, and subfamily status in 12 mutation-positive subjects with a 
heterozygous missense mutation p.C218G in WNT1. Expression information of all 187 microRNAs 
was used as input for hierarchical clustering. Average linkage and correlation were used as distance 
metrics. B) Volcano plot highlighting circulating miRNA regulation in 12 mutation-positive 
subjects with a heterozygous missense mutation p.C218G in WNT1. For every analyzed miRNA 
(dots) the observed fold difference (log2 transformed) between mutation positive and mutation 
negative subjects (x-axis) is shown in combination with the p-value derived from parametric t-
statistics. MicroRNAs with p<0.05 are labelled. 
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Figure 3. Heatmap with hierarchical clustering and scatterplots. A) The top 16 miRNAs (sorted 
according to p-value with p<0.1) in 12 mutation-positive subjects with a heterozygous missense 
mutation p.C218G in WNT1 were used for hierarchical clustering. Average linkage and correlation 
were used as distance metrics. B) – I) Normalized (global mean) delta Cq-values are shown for 
seven significantly regulated miRNAs (p<0.05) and miR-31-5p (p=0.053). Parametric t-test was 
applied. 
A)
B) C) D)
E) F) G)
H) I)
p=0.001 p=0.003
p=0.039
p=0.042 p=0.042 p=0.043
p=0.045 p=0.053
MN MP MN MP MN MP
MN MP MN MP MN MP
MN MP MN MP
MN
MP
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TABLES 
Table 1. Biochemical findings in 12 MP subjects with the heterozygous WNT1 mutation p.C218G and in 12 MN subjects 
 
SUBJECT 
CODE 
AGE 
(years) 
SEX 
S-Ca-ion 
(mmol/L) 
P-Pi 
(mmol/L) 
P-ALP 
(U/L) 
S-D-25 
(nmol/L) 
S-D-1,25 
(pmol/L) 
S-FGF23, I 
(pg/mL) 
S-iPTH 
(pg/mL)  
S-CTX-1 
(ng/mL) 
Mutation-positive subjects (n = 12) 
MP-1 11 F 1.26 1.35 258 90 173.0 42.00 22.0 1.792 
MP-2 13 M 1.25 1.66 247 112 94.3 77.27 7.6 2.946 
MP-3 13 F 1.32 1.23 122 75 140.0 66.36 23.8 1.349 
MP-4 17 F 1.25 1.12 77 116 96.4 75.45 31.4 0.562 
MP-5 19 M 1.27 0.82 83 31 168.0 32.90 22.6 0.452 
MP-6 34 F 1.24 1.25 84 105 44.70 63.77 40.0 0.147 
MP-7 44 F 1.32 0.89 51 82 66.8 51.04 24.9 0.102 
MP-9 52 M 1.24 0.86 50 74 172.0 54.68 24.3 0.196 
MP-12 54 F 1.22 1.34 74 136 64.1 46.14 30.8 0.710 
MP-13 63 M 1.24 1.09 52 146 114.0 66.10 29.3 0.107 
MP-15 71 F 1.24 1.39 72 88 124.0 41.17 18.2 0.199 
MP-17 76 M 1.28 0.85 84 89 87.6 54.94 47.9 0.161 
Mutation-negative subjects (n = 12) 
MN-2 9 F 1.28 1.55 257 68 165.0 49.45 33.0 1.685 
MN-3 10 M 1.32 1.42 313 70 192.0 37.03 12.6 1.636 
MN-6 24 M 1.24 1.53 67 39 144.0 43.93 26.2 0.861 
MN-7 27 F 1.27 1.38 60 70 127.0 51.56 36.6 0.731 
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Normal ranges according to HUSLAB Laboratory (females/males): S-Ca-ion: 1.16–1.3 mmol/L. P-Pi: 2–12 y, 1.2–1.8 mmol/L; 13–16 y, 1.1–1.8 
mmol/L; 17 y, 0.8–1.4 mmol/L; females .18 y, 0.76–1.41 mmol/L; males 18–49 y, 0.71–1.53 mmol/L; males .50 y, 0.71–1.23 mmol/L. P-ALP: 
8–9 y, 115–345 U/L; 10–11 y, 115–435/115–335 U/L; 12–13 y, 90–335/125–405 U/L; 14–15 y, 80–210/80–445 U/L; 16–18 y, 35–125/55–330 
U/L; .18 y, 35–105 U/L. S-D- 25: .50 nmol/L. Normal range for D-1,25 (1,25-dihydroxyvitamin D) according to United Medix Laboratories Ltd: 
48–190 pmol/L. Normal ranges for iFGF23 according to Immutopics International and Kainos Laboratories: 8.2–54.3 pg/mL. Normal ranges for 
iPTH and CTX according to IDS-iSYS Kit Manual (Immunodiagnostic Systems, Ltd., Bolton, UK): iPTH: adults, 11.5–78.4 pg/mL; CTX-1: 
premenopausal females, 0.034–0.635 ng/mL; post- menopausal females, 0.034–1.037 ng/mL; males, 0.038–0.724 ng/mL. Supranormal values 
are underlined, and subnormal values are in bold. 
 
Abbreviations: CTX, collagen type 1 cross-linked C-telopeptide; F, female; iFGF23, intact fibroblast growth factor 23; iPTH, intact parathyroid 
hormone; M, male; P-ALP, alkaline phosphatase; P-Pi, phosphate; S-Ca-ion, calcium; S-D-25, 25-hydroxyvitamin D. 
MN-8 30 M 1.24 0.88 104 54 117.0 56.49 38.6 0.376 
MN-11 32 M 1.27 0.51 67 41 92.8 65.84 29.8 0.332 
MN-12 37 F 1.27 1.13 52 60 134.0 39.52 33.4 0.213 
MN-13 43 M 1.22 0.84 61 68 74.1 74.16 35.6 0.284 
MN-14 49 F 1.22 1.05 63 90 82.9 43.66 46.1 0.152 
MN-15 53 M 1.28 1.09 50 73 57.2 61.17 56.4 0.268 
MN-16 57 F 1.26 1.08 83 39 109.0 41.17 49.7 0.624 
MN-17 59 M 1.28 1.02 94 21 71.1 77.79 35.8 0.223 
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Table 2. Differential expression for putative microRNA biomarker candidates with p-value <0.1 in 12 MP subjects with the heterozygous 
missense mutation p.C218G in WNT1 and in 12 MN subjects 
 
 
miRNA/miR = microRNA, let = lethal-gene, Cq = quantification value, MP = mutation-positive, MN = mutation-negative, AUC = area-under-
the-curve from ROC analysis. In bold, miRNAs that show p-values below 0.05.  
miRNA-ID 
Average 
(normalized delta Cq) 
Standard Deviation 
(Cq-value) 
Fold Change 
(log2-transformed) 
Fold Change 
(linear) 
Parametric 
t-Test 
ROC 
Analysis 
Group MP MN MP MN MP vs. MN MP vs. MN p-value AUC-value 
miR-22-3p 1.31 1.82 0.32 0.34 -0.51 0.70 0.001 0.896 
miR-34a-5p -2.92 -1.95 0.63 0.76 -0.97 0.51 0.003 0.868 
miR-423-5p 1.04 1.32 0.28 0.3 -0.27 0.83 0.039 0.743 
miR-18a-3p -2.05 -2.47 0.49 0.43 0.43 1.35 0.042 0.757 
miR-423-3p 1.14 1.45 0.35 0.31 -0.30 0.81 0.042 0.715 
miR-223-3p 9.17 8.82 0.4 0.37 0.35 1.27 0.043 0.757 
miR-143-5p -7.24 -5.88 1.91 0.95 -1.37 0.39 0.045 0.726 
miR-31-5p -5.36 -4.56 0.94 0.89 -0.80 0.57 0.053 0.729 
miR-425-3p -0.96 -1.27 0.27 0.42 0.31 1.24 0.053 0.774 
miR-874-3p -2.19 -1.68 0.67 0.54 -0.51 0.70 0.061 0.736 
miR-200b-3p -2.87 -3.39 0.55 0.73 0.52 1.43 0.071 0.688 
miR-330-3p -4.01 -4.55 0.42 0.91 0.55 1.46 0.086 0.684 
miR-103a-3p 4.69 5.01 0.39 0.44 -0.32 0.80 0.089 0.729 
let-7g-5p 3.83 4.06 0.31 0.3 -0.23 0.85 0.092 0.722 
miR-128-3p -1.78 -1.54 0.33 0.31 -0.24 0.85 0.092 0.698 
let-7d-5p 0.47 0.74 0.31 0.39 -0.26 0.84 0.095 0.705 
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Table 3. Previously reported data on the role in bone metabolism of the 7 discriminative miRNAs in WNT1 MP subjects.  
 
miRNA/miR = microRNA. 
miRNA-ID Finding in this study Role in bone metabolism Target proteins in bone References 
miR-22-3p Downregulated 
Negatively regulates osteogenesis and 
osteoblastogenesis 
WNT1, Tcf7, Ep300 10,35 
miR-34a-5p Downregulated 
Inhibits osteoblast differentiation and 
proliferation, increases osteoclast 
differentiation, elevates resorption, leads to 
decreased bone mineralization 
JAG1, WNT1 7,36,53 
miR-423-5p Downregulated 
Serum levels correlate negatively with 
fracture risk and bone quality 
- 57 
miR-18a-3p Upregulated Upregulated in osteosarcoma tissue - 58 
miR-223-3p Upregulated 
Regulates osteoclast differentiation, 
modulates expression of osteoclast marker 
genes NF-kB, TNF- α, and osteoprotegerin. 
NFIA, FGFR2, IKKα,  59-62 
miR-143-5p Downregulated 
Suppresses osteogenic differentiation, 
downregulated in osteosarcoma tissue 
Osx 63,64 
miR-31-5p Downregulated 
Inhibits osteogenesis and osteogenic 
differentiation of MSCs; increases 
osteoclastogenesis 
FZD3, RhoA, SATB2, 
RUNX2, Osterix 
8,9,65,66 
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Supplemental Figure 1. Serum concentrations of 1,25-dihydroxyvitamin D (S-D-1,25), 
intact fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and collagen 
type 1 cross-linked C-telopeptide (CTX-1) in 12 mutation-positive subjects (MP) with a 
heterozygous missense mutation p.C218G in WNT1 and in 12 mutation-negative 
subjects (MN).  
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Supplemental Figure 2. Quality control for serum samples from 12 mutation-positive 
subjects with a heterozygous missense mutation p.C218G in WNT1 and in 12 mutation-
negative subjects. Raw (not normalized) Cq-values are shown across all 24 samples for A) 
RNA spike-in controls, and B) reverse transcription and qPCR spike-in controls. C) Table 
summarizing mean, median, standard deviation, and CV (%) for spike-in Cq-values. D) A 
ratio of >7 between miR-23a-3p and miR-451a is indicative of hemolysis (red line).  
 
 
  
Spike-In Mean Median SD CV
UniSp3	IPC 20.3 20.3 0.15 11%
Cel-miR-39-3p	CP 25.5 25.4 0.22 16%
UniSp2	CP 17.1 17.0 0.24 18%
UniSp4	CP 23.9 23.8 0.18 13%
UniSp5	CP 30.7 30.7 0.30 23%
A)
B)
C)
D)
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Supplemental Figure 3. Exploratory data analysis of circulation miRNAs in 12 
mutation-positive subjects with a heterozygous missense mutation p.C218G in WNT1 
and in 12 mutation-negative subjects. Principal component analysis was performed based 
on all 187 quantified microRNAs. Red dots represent samples from mutation-positive 
subjects, blue dots represent samples from mutation-negative subjects.  
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Supplemental Figure 4. Scatterplots for 8 miRNAs in 12 mutation-positive subjects with 
p.C218G in WNT1 and in 12 mutation-negative subjects, and effect of bisphosphonate 
therapy on miRNAs. Normalized (global mean) delta Cq values are shown for 7 significantly 
regulated miRNAs (p<0.05) and miR-31-5p (p=0.053). One mutation-positive subject (MP-4) 
with on-going bisphosphonate treatment at the time of the study, is marked red.  
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Supplemental Table 1. Clinical findings in 12 mutation-positive subjects with a heterozygous WNT1 mutation p.C218G and in 12 mutation-
negative subjects. 
SUBJECT 
CODE 
AGE 
(years) 
SEX 
BMD Z-SCORES FRACTURES  OSTEOPOROSIS 
MEDICATION LS Fem WB Peripheral Vertebral 
Mutation-positive subjects (n = 12) 
MP-1 11 F -0.5 0.01 -0.5 1 0 - 
MP-2 13 M -1.1 -0.5 -0.7 4 0 - 
MP-3 13 F -2.1 -1.3 NA 1 0 - 
MP-4 17 F -2.5 -0.5 -1.0 9 0 PAM 2015-A 
MP-5 19 M -2.2 -0.1 NA 2 0 - 
MP-6 34 F -1.5 -2.2 -2.2 2 0 - 
MP-7 44 F -1.4 -0.9 NA 0 0 - 
MP-9 52 M -2.8 -1.3 -2.3 2 >3 - 
MP-12 54 F -3.3 -1.1 -1.5 0 0 - 
MP-13 63 M -2.2 -1.3 -3.5 3 >8 ZOL 2010, PTH 2013 
MP-15 71 F -1.5 -1.6 NA 9 >7 Estrogen N/A, RIS 2006 
MP-17 76 M 0.05 0.01 NA 1 >5 
ZOL 2008, PTH 2011-
2012 
Mutation-negative subjects (n = 12) 
MN-2 9 F N/A N/A N/A 1 0 - 
MN-3 10 M N/A N/A N/A 0 0 - 
MN-6 24 M -0.2 -0.5 -0.5 0 0 - 
MN-7 27 F N/A N/A N/A 0 0 - 
MN-8 30 M N/A N/A N/A 0 0 - 
MN-11 32 M N/A N/A N/A 0 0 - 
MN-12 37 F -0.4 -0.2 -0.6 0 0 - 
8 
 
 
 
 
 
 
 
 
 
BMD = bone mineral density measured with dual-energy X-ray absorptiometry, LS = lumbar spine, FEM = femoral neck/femoral head for under-
aged subjects, WB = whole body. PAM = pamidronate, ZOL = zsoledronic acid, PTH = teriparatide, RIS = risedronate. N/A = not available.   
A Last dose given 4 months prior to obtaining samples. 
 
  
MN-13 43 M N/A N/A N/A 0 N/A - 
MN-14 49 F N/A N/A N/A 0 0 - 
MN-15 53 M N/A N/A N/A 0 1 - 
MN-16 57 F -1.2 -1.1 -1.1 0 0 - 
MN-17 59 M N/A N/A N/A 1 0 - 
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Supplemental Table 2. Pearson correlation coefficients between significantly regulated 
miRNAs in 12 mutation-positive subjects with a heterozygous missense mutation 
p.C218G in WNT1 and in 12 mutation-negative subjects are shown.  
 
 
 
 
 
 
 
 
   
miR-22-3p miR-34a-5p miR-423-5p miR-18a-3p miR-423-3p miR-223-3p miR-143-5p miR-31-5p
miR-22-3p 1,00
miR-34a-5p 0,63 1,00
miR-423-5p 0,67 0,32 1,00
miR-18a-3p -0,27 -0,37 -0,15 1,00
miR-423-3p 0,12 0,05 -0,14 -0,33 1,00
miR-223-3p -0,21 -0,15 -0,06 0,04 0,09 1,00
miR-143-5p 0,45 0,38 0,09 -0,25 0,20 0,02 1,00
miR-31-5p 0,40 0,46 0,11 -0,54 -0,13 -0,48 0,34 1,00
